The U.S. Food and Drug Administration has delayed its decision on LNTH-2501, an imaging agent developed by Lantheus for detecting neuroendocrine tumors. The new decision date is June 29, 2026, about three months later than originally planned. The delay was requested to allow more time to review manufacturing details, not because of concerns about safety or effectiveness.
LNTH-2501 is a diagnostic radiopharmaceutical used to create gallium-68 edotreotide for PET imaging. It targets tumors that express somatostatin receptors, which are commonly found in neuroendocrine tumors of the digestive system, pancreas, and lungs. This imaging helps doctors diagnose the disease, determine its stage, and decide if patients are suitable for specialized treatments like radionuclide therapy.
The product is designed as a two-vial kit that can be prepared on-site, giving hospitals more flexibility compared to traditional centralized systems. Clinical studies showed that this imaging method performs as well as or better than older scan techniques, with high accuracy in detecting tumors.
Although the review timeline has been extended, the overall outlook remains positive. If approved, the product could launch later in 2026 and improve access to advanced imaging for patients with rare cancers.